CoChat
Sign Up
Cited by 39Viral-associated cancers and disordersHerpesvirus Infections and TreatmentsLymphoma Diagnosis and Treatment

Treatment of early AIDS-related Kaposiʼs sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial

Saiag, Philippe, Pavlovic, Mira, Clerici, Thierry, Feauveau, Véronique, Nicolas, Jean-Claude, Émilie, Dominique, Chastang, Claude·1998·AIDS
DOI 10.1097/00002030-199816000-00012
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To assess the efficacy and safety of all-trans-retinoic acid (ATRA), a retinoid with antitumour activity that inhibits in vitro the growth of Kaposi's sarcoma cells, in patients with low-risk AIDS-associated Kaposi's sarcoma. DESIGN: Non-randomized phase II study, using a group sequential procedure to determine whether the response rate to ATRA was above 10%. SETTING: Nine referral French centres. PATIENTS: Twenty HIV-seropositive men with CD4 cells > or = 200 x 10(6)/l, low-risk Kaposi's sarcoma [T0I0S0 according to the classification of AIDS Clinical Trials Group (ACTG)] not previously treated with systemic anti-Kaposi's sarcoma agents, and with at least four measurable lesions were included. INTERVENTIONS: ATRA was given orally 45 mg/m2 daily for 12 weeks. MAIN OUTCOME MEASURE: Tumour response evaluated according to ACTG criteria. RESULTS: Nineteen patients were evaluated for response: partial response, stabilization and progression were found in eight (42%), seven (37%), and four (21%) patients, respectively. Gradual flattening and lightening of lesions was observed in responders after at least 2 months of ATRA. All patients with partial response at week 12 pursued ATRA for another 15+/-7 weeks. Further improvement was observed in six patients. Median duration of response was 332 days. Cheilitis, transient headaches and skin dryness were the main toxicities noted. No significant changes in HIV viral burden or serum interleukin-6 pathways were observed. CONCLUSIONS: ATRA is well tolerated and effective enough in Kaposi's sarcoma patients to warrant further evaluation.

Integrity signals

Registry

Crossref · 10.1097/00002030-199816000-00012

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Saiag, P., Pavlovic, M., Clerici, T., Feauveau, V., Nicolas, J.-C., Émilie, D., & Chastang, C.
Affiliations
  • Hôpital Ambroise-Paré (FR)
  • Hôpital Rothschild (FR)
  • Inserm (FR)
Venue
AIDS
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1998-11
Volume
12
Issue
16
Pages
2169-2176
ISSN
0269-9370 (ISSN-L)
DOI
10.1097/00002030-199816000-00012
OpenAlex
W2338232804
Cited by
39
References
31
Citations by year
2022: 1 · 2020: 2 · 2017: 1
FWCI
1.75
Type
journal article
Language
en
Open access
closed
Locations
  • AIDS (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
Kaposi's sarcoma, AIDS-related Kaposi's sarcoma, all-trans retinoic acid, oral retinoids, tumor response, treatment efficacy, drug toxicity, cheilitis, HIV infection, CD4 count
MeSH terms
Acquired Immunodeficiency Syndrome, Administration, Oral, Adult, Antineoplastic Agents, Female, Follow-Up Studies, Humans, Male, Middle Aged, Sarcoma, Kaposi, Tretinoin, HIV-1, Cytokines, Viral Load

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review